Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence

Luspatercept has recently been approved for the treatment of beta-thalassemia and its use in clinical practice has been increasing. As it is the first erythroid maturation drug available for this diagnosis, the expertise about its use is still limited. To address this point, and to promote awareness...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, Filomena, Motta, Irene, Pinto, Valeria, Piolatto, Andrea, Ricchi, Paolo, Tartaglione, Immacolata, Origa, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094868/
https://www.ncbi.nlm.nih.gov/pubmed/37048666
http://dx.doi.org/10.3390/jcm12072584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094868/
https://www.ncbi.nlm.nih.gov/pubmed/37048666
http://dx.doi.org/10.3390/jcm12072584

Ejemplares similares